Journal article
Environmental risk assessment for the serotonin re‐uptake inhibitor fluoxetine: Case study using the European risk assessment framework
Abstract
The serotonin re-uptake inhibitor fluoxetine was selected for an environmental risk assessment, using the most recent European guideline (EMEA 2006) within the European Union (EU)-funded Environmental Risk Assessment of Pharmaceuticals (ERAPharm) project due to its environmental persistence, acute toxicity to nontarget organisms, and unique pharmacokinetics associated with a readily ionizable compound. As a widely prescribed psychotropic drug, …
Authors
Oakes KD; Coors A; Escher BI; Fenner K; Garric J; Gust M; Knacker T; Küster A; Kussatz C; Metcalfe CD
Journal
Integrated Environmental Assessment and Management, Vol. 6, No. S1, pp. 524–539
Publisher
Oxford University Press (OUP)
Publication Date
July 1, 2010
DOI
10.1002/ieam.77
ISSN
1551-3777